GSK slips as Jefferies downgrades on Zantac overhang

Sep. 08, 2022 10:20 AM ETGSK plc (GSK)SNY, SNYNFBy: Dulan Lokuwithana, SA News Editor1 Comment

Shipments Of A Generic Zantac Halted After FDA Warns Of Low Level Probable Carcinogen In Zantac And Its Generic Version

Drew Angerer/Getty Images News

American Depository Shares of GSK (NYSE:GSK) inched lower in the morning hours Thursday after Jefferies downgraded the U.K. pharma giant, citing uncertainty related to ongoing litigations over the heartburn medication Zantac.

Zantac was withdrawn from

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.